In patients with atrial fibrillation (AF), oral anticoagulation is used to prevent stroke and systemic embolism. In a common clinical scenario, AF patients frequently undergo invasive procedures requiring temporary interruption of oral anticoagulation, thereby potentially exposing such patients to increased risk of thromboembolism. Bridging anticoagulation has been used clinically to mitigate this perceived thromboembolic risk, though this practice may also increase risk of periprocedural bleeding. High-quality data has not previously existed to inform decision-making in this clinical situation of bridging anticoagulation. We discuss recent results from the BRIDGE trial and secondary analyses from recent phase 3 randomized clinical trials of direct-acting oral anticoagulant (DOAC) use in non-valvular AF, that inform periprocedural anticoagulation with bridging strategies in AF patients. Updated data from these current trials favor against a strategy of bridging anticoagulation for elective procedures in the majority of AF patients, low or moderate in thromboembolic risk. Bridging anticoagulation is associated with an increased risk of bleeding and no decreased risk of thromboembolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11886-016-0779-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction This case report illustrates the complexities of arrhythmogenic right ventricular cardiomyopathy (ARVC) and its thromboembolic complications resulting in top-of-basilar artery syndrome. We discuss the case of a 37-year-old male with ARVC who presented with acute onset of dizziness, imbalance, and vomiting, leading to the diagnosis of a top-of-basilar artery occlusion which was successfully treated. Case presentation This case highlights the diagnostic and acute treatment challenges in basilar artery occlusion (BAO) due to its non-specific symptoms and emphasizes the critical role of CT angiography in detecting occlusive thrombi for timely intervention.
View Article and Find Full Text PDFCangrelor Use for Viabahn Stent Graft Patency as Bridge to Coronary Artery Bypass Graft Surgery.
J Pharm Pract
January 2025
Department of Cardiothoracic Surgery, Jefferson Health Abington Hospital, Abington, PA, USA.
Article Synopsis
- Utilization of cangrelor as a bridging therapy to cardiac surgery has been noted for stent placement, but less so for endovascular revascularization.
- The case involves a 47-year-old female with a significant arterial dissection requiring a Viabahn endoprosthesis and subsequent cardiac procedures.
- A combination of cangrelor, aspirin, and bivalirudin was employed to manage the patient’s coronary disease and ensure the effectiveness of the surgical intervention, showcasing a multi-disciplinary approach in complex cases.
Enoxaparin-Induced Bullous Hemorrhagic Dermatosis and Enoxaparin Rechallenge: A Case Report.
J Pharm Pract
January 2025
Boston Medical Center, Boston, MA, USA.
A case of enoxaparin-induced bullous hemorrhagic dermatosis is reported. A 69-year-old male with past medical history including chronic atrial fibrillation and a re-do aortic valve replacement, anticoagulated on warfarin, received an enoxaparin bridge for a molar extraction. On day 7 after restarting enoxaparin post-procedure at a therapeutic dose of 90 mg every 12 hours, the patient noticed multiple small, dark, raised lesions on his forearm and ankle.
View Article and Find Full Text PDFChallenges with oral anticoagulants: bridging before surgery and concomitant use of non-steroidal anti-inflammatory drugs. Focus on revascularization of ischaemic cardiomyopathy and e-cigarettes after percutaneous coronary intervention.
Eur Heart J
January 2025
Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy.
ECMO for bridging lung transplantation.
Eur J Med Res
December 2024
Department of Critical Care Medicine, Shulan Hangzhou Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310022, People's Republic of China.
Background: With the shift in donor lung allocation from blood type and waiting order to the use of the lung allocation score (LAS) system, there are increasingly more cases of ECMO bridging lung transplantation. However, there are still some problems in case selection, implementation, and management.
Methods: We analyzed and summarized a series of data on ECMO bridging lung transplantation through an extensive literature review.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!